No One Cares if You Post or Not Post Results on Clinicaltrials.gov: Reports

The law requiring sponsors of clinical trials to post results from their trials to the clinicaltrials.gov website is almost 13 years old but many sponsors don’t care to comply and  the government agencies responsible to enforce this law, NIH and FDA, have no plans to compel the sponsors to do so. Ironically, many trials with … Read more

When FDA Plays God, Patients and Doctors Need to Step Up

The patients and doctors expect FDA to approve products based only on credible scientific data, but a few cases have shown that FDA does not always do that. In those cases, it falls on patients and their doctors to make sensible decisions based on facts before embarking on uncertain therapies carrying astronomical price tags.  FDA … Read more

Is FDA in Trouble: NY Times Thinks So 

FDA is approving new drugs and medical devices too fast, its reviewers are leaving for jobs in the industry they regulate, and it is critically short on resources, the editors of the New York Times opined this week. Another article this week in the Journal of American Medical Association (JAMA) by Harvard researchers, raised similar … Read more

Healthcare Administrative Costs Are Three Times The Cost of Drugs  

The high cost of healthcare in the US is often blamed on the high cost of prescription drugs, however, a recent study showed that the administrative costs play a much bigger role in our increased medical bills. The US healthcare costs is often compared to that in Canada, with laws being created to reimport drugs … Read more

Faster Approval Rates Show Increased FDA-Industry Collaboration 

For the last few years FDA has been approving more than 40 new drugs each year, a trend that continued in 2019 with the approval of 48 new drugs and biologics. But it is important to look beyond the numbers to fully understand the trend behind these. First let’s look at the numbers. This year’s … Read more

FDA’s Foreign GMP Audits Are Inadequate, Reports GAO 

The GAO reports this week that FDA is severely short of inspectors capable of auditing foreign sites, it gives up to 12 weeks’ notice to foreign sites prior to inspections giving them ample opportunity to clean-up and cover deficiencies, and its inspectors for foreign sites are given inadequate time to complete their job making them … Read more

The Conundrum of CBD Products for Medical Professionals

A perspective in the Journal of American Medical Association (JAMA) presents the unique challenge faced by medical professionals regarding use of CBD products by their patients. CBD products tread a fine line between legal and illegal products. Without any specific disease claims, CBD containing products can be sold as cosmetics or supplements. On the other … Read more

FDA’s Releases an Updated Guidance from Adaptive Trials

Last week FDA released the final guidance document for adaptive trials for drugs and biologics and it contains mostly the same information as the previous guidance documents by the Agency on the topic with some small but critical recommendations. FDA expects the sponsors to include the statistical analysis plan, the Data Monitoring Committee (DMC) charter, … Read more